Alumis (NASDAQ:ALMS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Alumis (NASDAQ:ALMS) in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a $19.00 price target on the stock.

A number of other research firms have also recently commented on ALMS. Oppenheimer initiated coverage on shares of Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research note on Thursday, November 14th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $26.57.

Alumis Trading Up 4.4 %

ALMS stock opened at $5.00 on Monday. The firm has a 50 day moving average of $6.22 and a 200 day moving average of $8.98. Alumis has a 52 week low of $4.36 and a 52 week high of $13.53.

Institutional Trading of Alumis

Several institutional investors and hedge funds have recently bought and sold shares of ALMS. Foresite Capital Management VI LLC purchased a new position in shares of Alumis during the 4th quarter valued at approximately $33,033,000. Samsara BioCapital LLC purchased a new position in shares of Alumis during the 3rd quarter valued at approximately $34,886,000. Geode Capital Management LLC purchased a new position in shares of Alumis during the 3rd quarter valued at approximately $3,266,000. Norges Bank purchased a new position in shares of Alumis during the 4th quarter valued at approximately $1,606,000. Finally, Foresite Capital Management V LLC increased its holdings in shares of Alumis by 3.5% during the 4th quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock valued at $45,426,000 after purchasing an additional 194,459 shares in the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.